• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Opioid Use for Low Back Pain and Neck Pain

Article

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


Last week, we reported on a study published in The Lancet that examined the safety and efficacy of a judicious short course of an opioid analgesic for acute low back pain (LBP) and neck pain in adults aged ≥18 years.

The study

Between February 2016 and March 2022, investigators recruited 347 individuals who presented at one of 157 primary care or emergency department sites in Australia with ≤12 weeks of LBP or neck pain (or both) of at least moderate intensity. Participants were randomly assigned to receive guideline-recommended care plus either an opioid (n=174) or placebo (n=173) for up to 6 weeks. Participants in the opioid group received up to 20 mg of modified-release oxycodone-naloxone per day orally.

The findings

Results showed no significant difference in pain scores at 6 weeks between the 2 cohorts, with a score of 2.78 in the opioid group and 2.25 in the placebo group.

Pain severity was not significantly different between groups at week 12, however, the between-group difference increased over time and by week 52 there was a small difference favoring placebo, according to researchers.

In addition, 35% of participants in the opioid group and 30% of those in the placebo group reported non-serious adverse events. The most common adverse events reported across both groups were nausea and vomiting, constipation, headache, dizziness, and somnolence.

A note from authors

"Opioids should not be recommended for acute non-specific low back pain or neck pain given that we found no significant difference in pain severity compared with placebo. This finding calls for a change in the frequent use of opioids for these conditions."

Click here for more details.


Related Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Related Content
© 2024 MJH Life Sciences

All rights reserved.